prostate cancer
Conditions
Interventions
treatment group:Intramuscular injection of testosterone propionate+Oral reverumide+Intravenous Carrilizumab
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. metastatic prostate cancer with Gleason score >= 7; 2. diagnosis of denuded resistant prostate cancer (CRPC): 3. Age 18 to 85 years; 4. failure of chemotherapy or patients who cannot or do not wish to receive chemotherapy after failure of novel endocrine therapy; 5. No obvious pain symptoms (NRS = 90g/L, white blood cells >= 3.5 x 10^9/L, and neutrophils >= 1.5 x 10^9/L, platelets >= 100 x 10^9/L; (2) Creatinine 60 ml/min; (3) Alanine aminotransferase (ALT) <= 1.5 x upper limit of normal (UNL); aspartate aminotransferase (AST) <= 1.5 x upper limit of normal (UNL); alkaline phosphatase (ALP) <= 1.5 x upper limit of normal (4) Total bilirubin (TBIL) <= 1.5 x upper limit of normal (UNL). 8. Be able to cooperate with treatment and follow-up regularly; 9. Life expectancy of enrolled cancer patients should not be <4 months; 10. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previously received BAT treatment; 2. Patients with high-risk skeletal lesions: bone scan nuclide accumulation, femoral or spinal metastases. Those with higher risk of pathological fracture or spinal cord compression; 3. Combined with the following diseases: autoimmune diseases, infectious diseases (HIV, HBV, HCV). Severe cardiovascular and cerebrovascular diseases (history of previous myocardial infarction and cerebral infarction), thrombosis-related diseases, intermittent qualitative pneumonia; 4. Patients with metastatic prostate cancer who require opioid pain relief; 5. More than 5 metastatic lesions in the lung or liver (non-specific nodules <=1 cm in the lung are not counted) 6. Patients with hypersensitivity to the active ingredients of ravelutamide or camrelizumab and any of the listed excipients need to be excluded; 7. Those who are participating in other clinical trials; 8. Those with a history of mental illness or those with poor compliance or who the researchers think are not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA remission rate after end of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence-free survival;objective response rate;overall survival;quality of life;Complications occurred during the treatment process;Comparison of pain scores after treatment; | — |
Countries
China
Contacts
Public ContactShengjie Liu
Beijing Hospital
Outcome results
None listed